Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2018

View Archived Issues

Lack of LAC is depression target, biomarker

High-fat diet leads to hair loss?

Enzyme discovery may improve drug design

Medicenna's IL-2 superkine shows promising preclinical activity

Neurodegenerative differences found between the presubiculum and entorhinal cortex in AD

JCR Pharmaceuticals presents data for JR-141 in mucopolysaccharidosis type II

HitGen to identify potential new therapies for tuberculosis and malaria

Salix enters microbiome collaboration with Cedars-Sinai Medical Center

Immatics begins phase I study of IMA-202 in solid tumors

IL-23 underlies the development of castration-resistant prostate cancer

DrugCendR recruiting participants for phase I study of CEND-1 in metastatic pancreatic cancer

Potential mechanism of purinergic receptor-mediated remyelination discovered

Global collaboration to develop first-in-class gene therapy for cystic fibrosis

U.S. researchers patent Nampt activators

Rodin Therapeutics presents HDAC1 and HDAC2 inhibitors

XinXiang Medical University divulges ANO5-targeting siRNAs

Regeneron, bluebird bio to jointly discover immune cell therapies for cancer

First patient dosed in extension cohort of amcure's phase I/Ib study of AMC-303

Phase II study of telacebec in tuberculosis begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...